-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
B-cell mature antigen (BCMA)-targeted therapies, including bispecific antibodies (BsAbs) and antibody-drug conjugates (ADCs), are promising treatments for multiple myeloma (MM), but the disease may progress
after use.
CARTITUDE-2 is a Phase 2 multi-cohort study evaluating the efficacy and safety of Cilta-cel, an anti-BCMA chimeric antigen receptor T cell therapy, in a variety of myeloma patient populations
.
Patients in Cohort C progressed
despite proteasome inhibitors, immunomodulatory drugs, anti-CD38 antibodies, and noncellular anti-BCMA immunotherapy.
A single Cilta-cel infusion
is given after lymphatic failure.
The primary endpoint was negative for minimal residual disease (MRD) (10-5
).
Overall, 20 patients were treated in the study (13 ADC exposed, 7 BsAb exposed, and 1 had previous BsAb exposure in the ADC group
).
Sixteen (80%) patients were refractory
to previous anti-BCMA therapy.
Progression-free survival rate across the cohort
At a median follow-up of 11.
Occurrence of adverse reactions
The most common adverse reactions are blood
.
In summary, Cilta-cel induces good responses in patients with relapsed/refractory multiple myeloma who have previously received anti-BCMA therapy and have exhausted other treatments
.
Original Source:
Cohen Adam D,Mateos Maria-Victoria,Cohen Yael C et al.
